p38 MAPK differentially controls NK activating ligands at transcriptional and post-transcriptional level on multiple myeloma cells

Alessandra Soriani, Cristiana Borrelli, Biancamaria Ricci, Rosa Molfetta, Alessandra Zingoni, Cinzia Fionda, Silvia Carnevale, Maria Pia Abruzzese, Maria Teresa Petrucci, Maria Rosaria Ricciardi, Giuseppe La Regina, Erica Di Cesare, Patrizia Lavia, Romano Silvestri, Rossella Paolini, Marco Cippitelli, Angela Santoni

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The mechanisms that regulate the expression of the NKG2D and DNAM-1 activating ligands are only partially known, but it is now widely established that their expression is finely regulated at transcriptional, post-transcriptional and post-translational level, and involve numerous stress pathways depending on the type of ligand, stressor, and cell context. We show that treatment of Multiple Myeloma (MM) cells with sub-lethal doses of Vincristine (VCR), an anticancer drug that inhibits the assembly of microtubules, stimulates the expression of NKG2D and DNAM-1 activating ligands, rendering these cells more susceptible to NK cell-mediated killing. Herein, we focused our attention on the identification of the signaling pathways leading to de novo surface expression of ULBP-1, and to MICA and PVR upregulation on VCR-treated MM cells, both at protein and mRNA levels. We found that p38MAPK differentially regulates drug-dependent ligand upregulation at transcriptional and post-transcriptional level. More specifically, we observed that ULBP-1 expression is attributable to both increased transcriptional activity mediated by ATM-dependent p53 activation, and enhanced mRNA stability; while the p38-activated E2F1 transcription factor regulates MICA and PVR mRNA expression. All together, our findings reveal a previously unrecognized activity of VCR as anticancer agent, and indicate that in addition to its established ability to arrest cell growth, VCR can also modulate the expression of NKG2D and DNAM-1 activating ligand on tumor cells and thus promoting NK cell-mediated immunosurveillance.

Original languageEnglish
Article numbere1264564
JournalOncoImmunology
Volume6
Issue number1
DOIs
Publication statusPublished - Jan 2 2017

Fingerprint

p38 Mitogen-Activated Protein Kinases
Multiple Myeloma
Vincristine
Ligands
Natural Killer Cells
Up-Regulation
E2F1 Transcription Factor
Immunologic Monitoring
Messenger RNA
RNA Stability
Microtubules
Pharmaceutical Preparations
Antineoplastic Agents
Growth
Neoplasms
Proteins

Keywords

  • Activating ligands
  • Chemoimmunotherapy
  • Multiple myeloma
  • NK cells

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

p38 MAPK differentially controls NK activating ligands at transcriptional and post-transcriptional level on multiple myeloma cells. / Soriani, Alessandra; Borrelli, Cristiana; Ricci, Biancamaria; Molfetta, Rosa; Zingoni, Alessandra; Fionda, Cinzia; Carnevale, Silvia; Abruzzese, Maria Pia; Petrucci, Maria Teresa; Ricciardi, Maria Rosaria; La Regina, Giuseppe; Di Cesare, Erica; Lavia, Patrizia; Silvestri, Romano; Paolini, Rossella; Cippitelli, Marco; Santoni, Angela.

In: OncoImmunology, Vol. 6, No. 1, e1264564, 02.01.2017.

Research output: Contribution to journalArticle

Soriani, A, Borrelli, C, Ricci, B, Molfetta, R, Zingoni, A, Fionda, C, Carnevale, S, Abruzzese, MP, Petrucci, MT, Ricciardi, MR, La Regina, G, Di Cesare, E, Lavia, P, Silvestri, R, Paolini, R, Cippitelli, M & Santoni, A 2017, 'p38 MAPK differentially controls NK activating ligands at transcriptional and post-transcriptional level on multiple myeloma cells', OncoImmunology, vol. 6, no. 1, e1264564. https://doi.org/10.1080/2162402X.2016.1264564
Soriani, Alessandra ; Borrelli, Cristiana ; Ricci, Biancamaria ; Molfetta, Rosa ; Zingoni, Alessandra ; Fionda, Cinzia ; Carnevale, Silvia ; Abruzzese, Maria Pia ; Petrucci, Maria Teresa ; Ricciardi, Maria Rosaria ; La Regina, Giuseppe ; Di Cesare, Erica ; Lavia, Patrizia ; Silvestri, Romano ; Paolini, Rossella ; Cippitelli, Marco ; Santoni, Angela. / p38 MAPK differentially controls NK activating ligands at transcriptional and post-transcriptional level on multiple myeloma cells. In: OncoImmunology. 2017 ; Vol. 6, No. 1.
@article{db271435f9b04c9b99231efc3788f943,
title = "p38 MAPK differentially controls NK activating ligands at transcriptional and post-transcriptional level on multiple myeloma cells",
abstract = "The mechanisms that regulate the expression of the NKG2D and DNAM-1 activating ligands are only partially known, but it is now widely established that their expression is finely regulated at transcriptional, post-transcriptional and post-translational level, and involve numerous stress pathways depending on the type of ligand, stressor, and cell context. We show that treatment of Multiple Myeloma (MM) cells with sub-lethal doses of Vincristine (VCR), an anticancer drug that inhibits the assembly of microtubules, stimulates the expression of NKG2D and DNAM-1 activating ligands, rendering these cells more susceptible to NK cell-mediated killing. Herein, we focused our attention on the identification of the signaling pathways leading to de novo surface expression of ULBP-1, and to MICA and PVR upregulation on VCR-treated MM cells, both at protein and mRNA levels. We found that p38MAPK differentially regulates drug-dependent ligand upregulation at transcriptional and post-transcriptional level. More specifically, we observed that ULBP-1 expression is attributable to both increased transcriptional activity mediated by ATM-dependent p53 activation, and enhanced mRNA stability; while the p38-activated E2F1 transcription factor regulates MICA and PVR mRNA expression. All together, our findings reveal a previously unrecognized activity of VCR as anticancer agent, and indicate that in addition to its established ability to arrest cell growth, VCR can also modulate the expression of NKG2D and DNAM-1 activating ligand on tumor cells and thus promoting NK cell-mediated immunosurveillance.",
keywords = "Activating ligands, Chemoimmunotherapy, Multiple myeloma, NK cells",
author = "Alessandra Soriani and Cristiana Borrelli and Biancamaria Ricci and Rosa Molfetta and Alessandra Zingoni and Cinzia Fionda and Silvia Carnevale and Abruzzese, {Maria Pia} and Petrucci, {Maria Teresa} and Ricciardi, {Maria Rosaria} and {La Regina}, Giuseppe and {Di Cesare}, Erica and Patrizia Lavia and Romano Silvestri and Rossella Paolini and Marco Cippitelli and Angela Santoni",
year = "2017",
month = "1",
day = "2",
doi = "10.1080/2162402X.2016.1264564",
language = "English",
volume = "6",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Taylor and Francis Inc.",
number = "1",

}

TY - JOUR

T1 - p38 MAPK differentially controls NK activating ligands at transcriptional and post-transcriptional level on multiple myeloma cells

AU - Soriani, Alessandra

AU - Borrelli, Cristiana

AU - Ricci, Biancamaria

AU - Molfetta, Rosa

AU - Zingoni, Alessandra

AU - Fionda, Cinzia

AU - Carnevale, Silvia

AU - Abruzzese, Maria Pia

AU - Petrucci, Maria Teresa

AU - Ricciardi, Maria Rosaria

AU - La Regina, Giuseppe

AU - Di Cesare, Erica

AU - Lavia, Patrizia

AU - Silvestri, Romano

AU - Paolini, Rossella

AU - Cippitelli, Marco

AU - Santoni, Angela

PY - 2017/1/2

Y1 - 2017/1/2

N2 - The mechanisms that regulate the expression of the NKG2D and DNAM-1 activating ligands are only partially known, but it is now widely established that their expression is finely regulated at transcriptional, post-transcriptional and post-translational level, and involve numerous stress pathways depending on the type of ligand, stressor, and cell context. We show that treatment of Multiple Myeloma (MM) cells with sub-lethal doses of Vincristine (VCR), an anticancer drug that inhibits the assembly of microtubules, stimulates the expression of NKG2D and DNAM-1 activating ligands, rendering these cells more susceptible to NK cell-mediated killing. Herein, we focused our attention on the identification of the signaling pathways leading to de novo surface expression of ULBP-1, and to MICA and PVR upregulation on VCR-treated MM cells, both at protein and mRNA levels. We found that p38MAPK differentially regulates drug-dependent ligand upregulation at transcriptional and post-transcriptional level. More specifically, we observed that ULBP-1 expression is attributable to both increased transcriptional activity mediated by ATM-dependent p53 activation, and enhanced mRNA stability; while the p38-activated E2F1 transcription factor regulates MICA and PVR mRNA expression. All together, our findings reveal a previously unrecognized activity of VCR as anticancer agent, and indicate that in addition to its established ability to arrest cell growth, VCR can also modulate the expression of NKG2D and DNAM-1 activating ligand on tumor cells and thus promoting NK cell-mediated immunosurveillance.

AB - The mechanisms that regulate the expression of the NKG2D and DNAM-1 activating ligands are only partially known, but it is now widely established that their expression is finely regulated at transcriptional, post-transcriptional and post-translational level, and involve numerous stress pathways depending on the type of ligand, stressor, and cell context. We show that treatment of Multiple Myeloma (MM) cells with sub-lethal doses of Vincristine (VCR), an anticancer drug that inhibits the assembly of microtubules, stimulates the expression of NKG2D and DNAM-1 activating ligands, rendering these cells more susceptible to NK cell-mediated killing. Herein, we focused our attention on the identification of the signaling pathways leading to de novo surface expression of ULBP-1, and to MICA and PVR upregulation on VCR-treated MM cells, both at protein and mRNA levels. We found that p38MAPK differentially regulates drug-dependent ligand upregulation at transcriptional and post-transcriptional level. More specifically, we observed that ULBP-1 expression is attributable to both increased transcriptional activity mediated by ATM-dependent p53 activation, and enhanced mRNA stability; while the p38-activated E2F1 transcription factor regulates MICA and PVR mRNA expression. All together, our findings reveal a previously unrecognized activity of VCR as anticancer agent, and indicate that in addition to its established ability to arrest cell growth, VCR can also modulate the expression of NKG2D and DNAM-1 activating ligand on tumor cells and thus promoting NK cell-mediated immunosurveillance.

KW - Activating ligands

KW - Chemoimmunotherapy

KW - Multiple myeloma

KW - NK cells

UR - http://www.scopus.com/inward/record.url?scp=85015270684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015270684&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2016.1264564

DO - 10.1080/2162402X.2016.1264564

M3 - Article

AN - SCOPUS:85015270684

VL - 6

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

IS - 1

M1 - e1264564

ER -